Construction and characterization of multiple human colon cancer cell lines for inducibly regulated gene expression

Journal of Cellular Biochemistry

Volumn 94, Issue 6, 2005, Pages 1148-1162

  Welman, Arkadiusz ^a   Cawthorne, Christopher ^a,b   Barraclough, Jane ^a   Smith, Nigel ^a   Griffiths, Gareth J ^a   Cowen, Rachel L ^b   Williams, Judith C ^b   Stratford, Ian J ^b   Dive, Caroline ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Colon cancer; Doxycycline; Model system; rtTA; rtTA2s M2; Tet On

Indexed keywords

ANTINEOPLASTIC AGENT; DOXYCYCLINE; GREEN FLUORESCENT PROTEIN; LUCIFERASE; ONCOPROTEIN; ONCOPROTEIN K RAS4B; RED FLUORESCENT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; CELL TRANSFORMATION; CELL TYPE; CLONE; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE K RAS; ONCOGENE K RAS4B; ONCOGENE SRC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TUMOR XENOGRAFT; WILD TYPE;

BLOTTING, WESTERN; CELL LINE, TUMOR; CYTOMEGALOVIRUS; DOXYCYCLINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PLASMIDS; PROMOTER REGIONS (GENETICS); SUBCELLULAR FRACTIONS; TRANSGENES;

EID: 24944522678     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20342     Document Type: Article

References (56)

1. Barker N, Clevers H. 2001. Tumor environment: A potent driving force in colorectal cancer? Trends Mol Med 7:535-537.
2. Baron U, Bujard H. 2000. Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances. Methods Enzymol 327:401-421.
3. Berens C, Hillen W. 2003. Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes. Eur J Biochem 270:3109-3121.
4. Chtarto A, Bender HU, Hanemann CO, Kemp T, Lehtonen E, Levivier M, Brotchi J, Velu T, Tenenbaum L. 2003. Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther 10:84-94.
5. Chung S, Andersson T, Sonntag KC, Bjorklund L, Isacson O, Kim KS. 2002. Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines. Stem Cells 20:139-145.
6. Corbel SY, Rossi FM. 2002. Latest developments and in vivo use of the Tet system: Ex vivo and in vivo delivery of tetracycline-regulated genes. Curr Opin Biotechnol 13:448-452.
7. Cubitt AB, Heim R, Adams SR, Boyd AE, Gross LA, Tsien RY. 1995. Understanding, improving and using green fluorescent proteins. Trends Biochem Sci 20:448-455.
8. Dietz S, Rother K, Bamberger C, Schmale H, Mossner J, Engeland K. 2002. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73. FEBS Lett 525:93-99.
9. Fischer M, Kaech S, Knutti D, Matus A. 1998. Rapid actin-based plasticity in dendritic spines. Neuron 20:847-854.
10. Frame MC. 2002. Src in cancer: Deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602:114-130.
11. Fregien N, Davidson N. 1986. Activating elements in the promoter region of the chicken beta-actin gene. Gene 48:1-11.
12. Fussenegger M. 2001. The impact of mammalian gene regulation concepts on functional genomic research, metabolic engineering, and advanced gene therapies. Biotechnol Prog 17:1-51.
13. Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, Hamelin R. 2001. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20:5025-5032.
14. Gill S, Thomas RR, Goldberg RM. 2003. Review article: Colorectal cancer chemotherapy. Aliment Pharmacol Ther 18:683-692.
15. Gisselsson D. 2003. Chromosome instability in cancer: How, when, and why? Adv Cancer Res 87:1-29.
16. Gopalkrishnan RV, Christiansen KA, Goldstein NI, DePinho RA, Fisher PB. 1999. Use of the human EF-1alpha promoter for expression can significantly increase success in establishing stable cell lines with consistent expression: A study using the tetracycline-inducible system in human cancer cells. Nucleic Acids Res 27:4775-4782.
17. Gorman CM, Rigby PW, Lane DP. 1985. Negative regulation of viral enhancers in undifferentiated embryonic stem cells. Cell 42:519-526.
18. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. 1995. Transcriptional activation by tetracyclines in mammalian cells. Science 268:1766-1769.
19. Hagmann J, Grob M, Welman A, van Willigen G, Burger MM. 1998. Recruitment of the LIM protein hic-5 to focal contacts of human platelets. J Cell Sci 111:2181-2188.
20. Hagmann J, Burger MM, Dagan D. 1999. Regulation of plasma membrane blebbing by the cytoskeleton. J Cell Biochem 73:488-499.
21. Hahn WC, Weinberg RA. 2002. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331-341.
22. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
23. Hasegawa T, Nakada S, Nakajima T, Oda K, Kawata M, Kimura H, Sekiya S. 1990. Expression of various viral and cellular enhancer-promoters during differentiation of human embryonal carcinoma cells. Differentiation 42:191-198.
24. Heyer J, Yang K, Lipkin M, Edelmann W, Kucherlapati R. 1999. Mouse models for colorectal cancer. Oncogene 18:5325-5333.
25. Hoffman RM. 1999. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: A bridge to the clinic. Invest New Drugs 17:343-359.
26. Hofmann A, Nolan GP, Blau HM. 1996. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sci USA 93:5185-5190.
27. Izumi M, Gilbert DM. 1999. Homogeneous tetracycline-regulatable gene expression in mammalian fibroblasts. J Cell Biochem 76:280-289.
28. Jang SK, Wimmer E. 1990. Cap-independent translation of encephalomyocarditis virus RNA: Structural elements of the internal ribosomal entry site and involvement of a cellular 57-kD RNA-binding protein. Genes Dev 4:1560-1572.
29. Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159-170.
30. Knott A, Garke K, Urlinger S, Guthmann J, Muller Y, Thellmann M, Hillen W. 2002. Tetracycline-dependent gene regulation: Combinations of transregulators yield a variety of expression windows. Biotechniques 32:796-806.
31. Kobayashi T, Sawa H, Morikawa J, Zhang W, Shiku H. 2000. Bax induction activates apoptotic cascade via mitochondrial cytochrome c release and Bax overexpression enhances apoptosis induced by chemotherapeutic agents in DLD-1 colon cancer cells. Jpn J Cancer Res 91:1264-1268.
32. Koponen JK, Kankkonen H, Kannasto J, Wirth T, Hillen W, Bujard H, Yla-Herttuala S. 2003. Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo. Gene Ther 10:459-466.
33. Kosuga M, Enosawa S, Li XK, Suzuki S, Matsuo N, Yamada M, Roy-Chowdhury J, Koiwai O, Okuyama T. 2000. Strong, long-term transgene expression in rat liver using chicken beta-actin promoter associated with cytomegalovirus immediate-early enhancer (CAG promoter). Cell Transplant 9:675-680.
34. Li M, Hantzopoulos PA, Banerjee D, Zhao SC, Schweitzer BI, Gilboa E, Bertino JR. 1992. Comparison of the expression of a mutant dihydrofolate reductase under control of different internal promoters in retroviral vectors. Hum Gene Ther 3:381-390.
35. Miller K, Rizzino A. 1995. The function of inducible promoter systems in F9 embryonal carcinoma cells. Exp Cell Res 218:144-150.
36. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
37. Narayan S, Roy D. 2003. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer 2:41.
38. Park JG, Gazdar AF. 1996. Biology of colorectal and gastric cancer cell lines. J Cell Biochem Suppl 24:131-141.
39. Qu Z, Thottassery JV, Van Ginkel S, Manuvakhova M, Westbrook L, Roland-Lazenby C, Hays S, Kern FG. 2004. Homogeneity and long-term stability of tetracycline-regulated gene expression with low basal activity by using the rtTA2S-M2 transactivator and insulator-flanked reporter vectors. Gene 327:61-73.
40. Ramezani A, Hawley TS, Hawley RG. 2000. Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther 2:458-469.
41. Rangarajan A, Weinberg RA. 2003. Opinion: Comparative biology of mouse versus human cells: Modelling human cancer in mice. Nat Rev Cancer 3:952-959.
42. Roelandse M, Welman A, Wagner U, Hagmann J, Matus A. 2003. Focal motility determines the geometry of dendritic spines. Neuroscience 121:39-49.
43. Rossi FM, Guicherit OM, Spicher A, Kringstein AM, Fatyol K, Blakely BT, Blau HM. 1998. Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16. Nat Genet 20:389-393.
44. Salucci V, Scarito A, Aurisicchio L, Lamartina S, Nicolaus G, Giampaoli S, Gonzalez-Paz O, Toniatti C, Bujard H, Hillen W, Ciliberto G, Palombo F. 2002. Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Ther 9:1415-1421.
45. Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ, Coppola D. 2003. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 63:7708-7716.
46. Sleigh MJ. 1987. Differential regulation of viral and cellular genes in F9 mouse embryonal carcinoma cells. Nucleic Acids Res 15:9379-9395.
47. Terry NH, White RA. 2001. Cell cycle kinetics estimated by analysis of bromodeoxyuridine incorporation. Methods Cell Biol 63:355-374.
48. Teschendorf C, Warrington KH, Jr., Siemann DW, Muzyczka N. 2002. Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. Anticancer Res 22:3325-3330.
49. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. 2000. Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 97:7963-7968.
50. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, van den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H. 2002. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111:241-250.
51. van Roessel P, Brand AH. 2002. Imaging into the future: Visualizing gene expression and protein interactions with fluorescent proteins. Nat Cell Biol 4:E15-E20.
52. Wang WS, Chen PM, Hsiao HL, Ju SY, Su Y. 2003. Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells. Oncogene 22:3297-3306.
53. Welman A, Burger MM, Hagmann J. 2000. Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targetting and transformation. Oncogene 19:4582-4591.
54. Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE. 2002. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 21:7797-7807.
55. Xu R, Janson CG, Mastakov M, Lawlor P, Young D, Mouravlev A, Fitzsimons H, Choi KL, Ma H, Dragunow M, Leone P, Chen Q, Dicker B, During MJ. 2001. Quantitative comparison of expression with adenoassociated virus (AAV-2) brain-specific gene cassettes. Gene Ther 8:1323-1332.
56. Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA. 2002. Tetracycline-controlled transcriptional regulation systems: Advances and application in transgenic animal modeling. Semin Cell Dev Biol 13:121-128.